Invests in force life insurance products as an integrated alternative asset manager. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 21.7× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Sales run at $114.3M a year. A small number, but proof the product has real buyers.
It pays out $2.47 per share each year — regular cash for whoever holds the stock.
A loss of $24.0M against $114.3M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.